Cuprina (CUPR) said Monday it has signed an agreement to acquire the right to market medical maggots for use in debridement therapy to treat chronic wounds in the US.
The agreement was signed with Ronald Sherman, who holds a 2004 US Food and Drug Administration clearance to market Lucilia sericata maggots, giving Cuprina the right to manufacture, sell, use, and distribute the medical maggots and associated dressings for maggot debridement therapy, according to a statement.
Sherman will join the company as medical and scientific director in September, Cuprina said.
Cuprina also said it is updating a submission to the FDA to seek approval for the use of another species of medical maggots, Lucilia cuprina, and could receive marketing clearance within 90 business days.
Price: 7.55, Change: -0.02, Percent Change: -0.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.